Skip Navigation


International Immunology Advance Access originally published online on August 19, 2009
International Immunology 2009 21(10):1185-1197; doi:10.1093/intimm/dxp084
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
21/10/1185    most recent
dxp084v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hwang, S.-A.
Right arrow Articles by Actor, J. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hwang, S.-A.
Right arrow Articles by Actor, J. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2009. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Lactoferrin modulation of BCG-infected dendritic cell functions

Shen-An Hwang and Jeffrey K. Actor

Department of Pathology and Laboratory Medicine, Medical School, Program in Molecular Pathology, University of Texas–Houston Medical School, 6431 Fannin, Houston, TX 77030, USA

Correspondence to: Jeffrey K. Actor; E-mail: jeffrey.k.actor{at}uth.tmc.edu

Lactoferrin, an 80-kDa iron-binding protein with immune modulating properties, is a unique adjuvant component able to enhance efficacy of the existing Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine to protect against murine model of tuberculosis. Although identified as having effects on macrophage presentation events, lactoferrin's capability to modulate dendritic cells (DCs) function when loaded with BCG antigens has not been previously recognized. In this study, the potential of lactoferrin to modulate surface expression of MHC II, CD80, CD86 and CD40 from bone marrow-derived dendritic cells (BMDCs) was examined. Generally, lactoferrin decreased pro-inflammatory cytokines [tumor necrosis factor (TNF)-{alpha}, IL-6 and IL-12p40] and chemokines [macrophage inflammatory protein (MIP)-1{alpha} and MIP-2] and increased regulatory cytokine, transforming growth factor-β1 and a T-cell chemotatic factor, monocyte chemotactic protein-1, from uninfected or BCG-infected BMDCs. Culturing BCG-infected BMDCs with lactoferrin also enhanced their ability to respond to IFN-{gamma} activation through up-regulation of maturation markers: MHC I, MHC II and the ratio of CD86:CD80 surface expression. Furthermore, lactoferrin-exposed BCG-infected DCs increased stimulation of BCG-specific CD3+CD4+ splenocytes, as defined by increasing IFN-{gamma} production. Finally, BCG-/lactoferrin-vaccinated mice possessed an increased pool of BCG antigen-specific IFN-{gamma} producing CD3+CD4+CD62L– splenocytes. These studies suggest a mechanism in which lactoferrin may exert adjuvant activity by enhancing DC function to promote generation of antigen-specific T cells.

Keywords: adjuvant, BCG, dendritic cells, lactoferrin, tuberculosis

Transmitting editor: H. Karasuyam

Received 19 February 2009, accepted 28 July 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.